Giacomin Jon L
Insider transactions at 2 companies
This page shows all SEC Form 4 filings attributed to Giacomin Jon L. Form 4 disclosures are required whenever a corporate insider — director, officer, or 10%+ shareholder — buys, sells, or receives company stock. Each row represents a separate reported transaction. All data is sourced directly from the SEC EDGAR public database.
| Company | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| ORGO | Award / Grant | 49,575 | — | — | Feb 19, 2025 | |
| ORGO | Award / Grant | 51,020 | — | — | Feb 21, 2024 | |
| ORGO | Award / Grant | 65,737 | — | — | Feb 22, 2023 | |
| ORGO | Award / Grant | 20,547 | — | — | Feb 15, 2022 | |
| ORGO | Award / Grant | 5,319 | — | — | May 7, 2021 | |
| CAH | CEO, Medical Segment | Tax Withholding | 6,854 | $42.41 | $290,678 | Aug 15, 2019 |
| CAH | CEO, Medical Segment | Tax Withholding | 4,411 | $55.50 | $244,811 | Feb 15, 2019 |
| CAH | CEO, Medical Segment | Sale | 2,890 | $51.95 | $150,136 | Aug 20, 2018 |
| CAH | CEO, Medical Segment | Tax Withholding | 3,387 | $50.17 | $169,926 | Aug 15, 2018 |
| CAH | CEO, Medical Segment | Sale | 2,271 | $69.12 | $156,972 | Feb 20, 2018 |
| CAH | CEO, Pharmaceutical Segment | Tax Withholding | 845 | $67.46 | $57,004 | Sep 15, 2017 |
| CAH | CEO, Pharmaceutical Segment | Tax Withholding | 8,243 | $66.76 | $550,303 | Aug 15, 2017 |
| CAH | CEO, Pharmaceutical Segment | Award / Grant | 10,976 | — | — | Aug 8, 2017 |
| CAH | CEO, Pharmaceutical Segment | Sale | 23,270 | $72.87 | $1,695,685 | May 12, 2017 |
| CAH | CEO, Pharmaceutical Segment | Tax Withholding | 845 | $75.26 | $63,595 | Sep 15, 2016 |
| CAH | CEO, Pharmaceutical Segment | Option Exercise | 16,100 | $27.29 | $439,369 | Aug 16, 2016 |
| CAH | CEO, Pharmaceutical Segment | Award / Grant | 6,878 | — | — | Aug 4, 2016 |
| CAH | CEO, Pharmaceutical Segment | Tax Withholding | 844 | $84.31 | $71,158 | Sep 15, 2015 |
| CAH | CEO, Pharmaceutical Segment | Tax Withholding | 3,707 | $84.27 | $312,389 | Aug 15, 2015 |
| CAH | CEO, Pharmaceutical Segment | Award / Grant | 6,960 | — | — | Aug 4, 2015 |